TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Equity/Stock(s)/Options - Biostar Ventures
• Grant Support/Research Contract - Medtronic; Teleflex; Biotronik; Orbus Neich; Supira Medical
• Consultant Fee/Honoraria/Speaker's Bureau - Medtronic